- Joseph Lee Hollander Professor in Pediatric Rheumatology at University of Pennsylvania School of Medicine (2010 – 2011)
- Joseph Lee Hollander Associate Professor in Pediatric Rheumatology at University of Pennsylvania School of Medicine (2009 – 2010)
- Joseph Lee Hollander Chair in Pediatric Rheumatology at University of Pennsylvania School of Medicine (1999 – 2009)
- Adjunct Professor of Pediatrics at University of Pennsylvania School of Medicine (2011 – 2014)
Molecular mechanisms of lymphocyte activation.
Immunogenetics of inflammatory arthritis and lupus.
Mechanisms of HIV persistence and immune dysregulation;
identification of viral and cellular determinants regulating apoptosis, immune suppression and latency
Mechanisms of HIV persistence and immune dysregulation, identification of viral and cellular determinants regulating HIV-induced apoptosis, immune suppression and latency
Molecular mechanisms of lymphocyte activation
The Finkel lab focuses on molecular mechanisms of lymphocyte activation in health and disease, with an emphasis on mechanisms of viral persistence and immune dysregulation. Current goals include identification and mechanistic dissection of viral and cellular gene products regulating apoptosis, immune suppression and viral latency. To this end, the Finkel lab has demonstrated that the HIV surface protein, gp120, primes T cells for cell death by apoptosis. These results suggest a mechanism for the massive CD4 T cell depletion in AIDS, particularly in the face of concurrent infection and antigenic challenge with other organisms. Subsequent in vivo studies showed that this apoptosis occurs predominantly in healthy bystander cells and only rarely in infected cells, suggesting that HIV encodes or induces expression of survival genes. Using a variety of molecular techniques including microarray and gene silencing, we have identified known and novel cellular gene products that may regulate T cell apoptosis and latency in HIV infection. Pre-clinical studies are underway to test candidate drugs that may prevent or reverse HIV latency. In other studies defining signaling mechanisms of healthy lymphocytes, we showed that T cells, like some non-immune cells, use the cytoskeleton to transduce activating signals. Current work uses human blood cells and genetically engineered animals to address mechanisms of initiation of T cell activation. A novel artificial membrane system has been developed that closely mimics the cell surface and, in conjunction with real-time digital immunofluorescence microscopy, provides a valuable research tool to study the immune synapse. Finally, we are using animal models, in conjunction with dual photon laser microscopy, to develop novel therapies for autoimmune and infectious disease, including non-myeloablative bone marrow transplantation for lupus, and immune adjuvants for DNA vaccination against agents of bioterror.
Testing of pro-apoptotic lentiviral vector gene therapy, using TAT-inducible small hairpin RNA (shRNA) to target survival proteins in HIV infection
Characterization of anti-apoptotic gene products identified from chronically HIV infected cells by suppression subtractive hybridization
Determine the role of reactive oxygen species in HIV-induced T-cell apoptosis
Determine the mechanism of the anti-apoptotic protein, DDIT4, in HIV-infected T-cell survival
Jiang-Fang Wang - Senior Research Associate
Mark Ma - Research Assistant Professor
Debra Shivers - Senior Research Technician
- M.A. Hon., University of Pennsylvania (1999)
- Ph.D., Biochemistry/Biophysics, Stanford University (1984)
- M.D., Stanford University (1982)
- B.S., Stanford University (1975)
- Wang JF, Reuschel EL, O'Doherty U, Yu XF, Finkel TH. A cautionary note: HIV 1 env vectors pseudotyped with an HIV-1 envelope are cabable of multiple rounds of infection (in revision). PLoS Pathogens. 2013.
- Rider LG, Shah M, Mamyrova G, Huber AM, Malley JD, Rice MM, Targoff IN, Miller FW, Childhood Myositis Heterogeneity Collaborative Study Group (Finkel TH). The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies (in press). Medicine. 2013.
- Shah M, Mamyrova G, Targoff IN, Huber AM, Malley J, Rice M, Miller FW, Rider LG, Childhood Myositis Heterogeneity Collaborative Study Group (Finkel TH). The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine. Vol 92. 2013:25-4.
- Cheng T, Choi Y, Finkel TH, Tsao PY, Ji MQ, Eisenberg RA. Tumor necrosis factor-receptor associated factor 1 influences KRN/I-Ag7 mouse arthritis autoantibody production (in press). Journal of Clinical Immunology. 2013.
- Ma Z, Finkel TH. Mechanical force in T cell receptor signal initiation. Frontiers in Immunology. Vol 3. 2012:217.
- Ma Z, Janmey PA, Sharp KA and Finkel TH. Improved method of preparation of supported planar lipid bilayers as artificial membranes for antigen presentation. Microscopy Research and Technique. Vol 74. 2011:1174-1185.
- Molitoris JK, McColl K, Swerdlow S, Matsuyama M, Lam M, Finkel TH, Matsuyama S, Distelhorst CW. Glucocorticoid elevation of dexamethasone-induced gene 2 (Dig2/RTP801/REDD1) protein mediates autophagy in lymphocytes. Journal of Biological Chemistry. Vol 286. 2011:30181-30189.
- Wang JF, Reuschel E, Shackelford JM, Jeant L, shivers D, Diehl A, Yu XF and Finkel TH. HIV-1 Vif promotes the G1-to-S phase cell cycle transtion. Blood. Vol 227. 2011:1260-1269.
- Weiss PF, Klink AJ, Behrens E, Sherry DD, Finkel TH, Feudtner C, and Keren R. Enthesitis in an inception cohort of enthesitis-related arthritis. Arthritis Care and Research. Vol 63. 2011:1307-1312.
- Rider L, Wu L, Mamyrova G, Targoff I, Miller F, for the Childhood Myositis Heterogeneity Collaborative Study Group (Finkel TH). Environmental factors preceding illness onset in the juveile idiopathic inflammatory myopathies. Rheumatology. Vol 49. 2010:2381-2390.